RPG Life Sciences (RPGLIFE) investor relations material

Executive summary

• Achieved robust Q1 FY27 performance with 15.8% revenue growth and 17.0% PAT growth year-over-year.

• Entered the Top 50 Pharma Companies in India as of June 2026, advancing from rank 62 in March 2025.

• Received three industry awards in Q1 FY27, including Top Nephrology Company and recognition for AI-driven sales force effectiveness.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board of Directors and reviewed by statutory auditors, with no material misstatements identified.

Financial highlights

• Revenue from operations rose to ₹195.7 crore in Q1 FY27, up 15.8% from ₹168.9 crore in Q1 FY26.

• EBITDA increased by 17.9% to ₹48.0 crore, with EBITDA margin improving to 24.5%.

• PAT (excluding exceptional items) grew by 17.0% to ₹30.8 crore, with PAT margin at 15.7%.

• Consolidated revenue from operations for Q1 FY27 was ₹19,569 lakhs, with consolidated net profit at ₹3,076 lakhs, both showing year-over-year growth.

• Basic and diluted EPS for Q1 FY27 stood at ₹18.49 (standalone) and ₹18.60 (consolidated), up from ₹15.90 in Q1 FY26.

Outlook and guidance

• Strategic focus on portfolio development, mega-brand building, and expanding API business.

• Ongoing investments in capacity, digital transformation, and new product launches across segments.

• M&A opportunities under evaluation to drive growth synergies.

• The transfer of the API division to a wholly owned subsidiary is expected to conclude upon receipt of regulatory approvals and completion of conditions precedent.